Literature DB >> 15979274

Chickenpox in pregnancy: revisited.

Michael Paul Tan1, Gideon Koren.   

Abstract

Varicella infection during the first and second trimester of pregnancy may increase the risk for congenital varicella syndrome 0.5-1.5% above the baseline risk for major malformation. Third trimester infection may lead to maternal pneumonia which can be life threatening if not treated appropriately. Varicella-zoster immune globulin (VZIG) should be administered as soon as possible preferably within 96 h from exposure to prevent maternal infection or subsequent complications. Later than 96 h, the effectiveness of VZIG has not been evaluated. Neonatal varicella is more severe if maternal rash appears 5 days prior to or 2 days after delivery. The newborn should be given VZIG immediately. Intravenous acyclovir is recommended for maternal pneumonia and severely affected neonate. No controlled study has yet evaluated the effectiveness of acyclovir or valacyclovir for postexposure prophylaxis to pregnant women or neonates. Unlike primary varicella infection in pregnancy, herpes zoster has not been documented to cause complications unless in the disseminated form. The advent of advanced imaging techniques and molecular biotechniques has improved prenatal diagnosis. With increase use of vaccination, the incidence of chickenpox in pregnancy is expected to decline in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979274     DOI: 10.1016/j.reprotox.2005.04.011

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  18 in total

Review 1.  [Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics].

Authors:  Miriam Wittek; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Klin (Munich)       Date:  2010-05-26

Review 2.  Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin.

Authors:  Arlan Cohen; Panagis Moschopoulos; Panagis Maschopoulos; Richard E Stiehm; Gideon Koren
Journal:  CMAJ       Date:  2011-01-24       Impact factor: 8.262

3.  Preventing congenital varicella syndrome with immunization.

Authors:  Andreas Sauerbrei
Journal:  CMAJ       Date:  2011-01-24       Impact factor: 8.262

Review 4.  Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections.

Authors:  A Sauerbrei; P Wutzler
Journal:  Med Microbiol Immunol       Date:  2006-12-16       Impact factor: 3.402

Review 5.  Varicella-zoster virus (chickenpox) infection in pregnancy.

Authors:  Ronald F Lamont; Jack D Sobel; D Carrington; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Edi Vaisbuch; Roberto Romero
Journal:  BJOG       Date:  2011-05-18       Impact factor: 6.531

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 7.  Emerging Role of Zika Virus in Adverse Fetal and Neonatal Outcomes.

Authors:  Alice Panchaud; Miloš Stojanov; Anne Ammerdorffer; Manon Vouga; David Baud
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

8.  Validity of self-reported varicella disease history in pregnant women attending prenatal clinics.

Authors:  Barbara Watson; Rachel Civen; Meredith Reynolds; Karl Heath; Dana Perella; Tina Carbajal; Laurene Mascola; Aisha Jumaan; Laura Zimmerman; Abike James; Carlene Quashi; Scott Schmid
Journal:  Public Health Rep       Date:  2007 Jul-Aug       Impact factor: 2.792

9.  Varicella-zoster immunoglobulin treatment in pregnant women in Denmark from 2005 to 2015: descriptive epidemiology and follow-up.

Authors:  C Jespersen; I G Helmuth; T G Krause
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

10.  Chicken pox in pregnancy : an obstetric concern.

Authors:  Viroj Wiwanitkit
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.